Logo image of AVTE

AEROVATE THERAPEUTICS INC (AVTE) Stock Fundamental Analysis

NASDAQ:AVTE - Nasdaq - US0080641071 - Common Stock - Currency: USD

2.45  -0.02 (-0.81%)

After market: 2.45 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AVTE. AVTE was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTE as it has an excellent financial health rating, but there are worries on the profitability. AVTE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AVTE had negative earnings in the past year.
In the past year AVTE has reported a negative cash flow from operations.
AVTE had negative earnings in each of the past 5 years.
AVTE had a negative operating cash flow in each of the past 5 years.
AVTE Yearly Net Income VS EBIT VS OCF VS FCFAVTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of AVTE (-93.02%) is worse than 73.10% of its industry peers.
Looking at the Return On Equity, with a value of -105.12%, AVTE is in line with its industry, outperforming 45.13% of the companies in the same industry.
Industry RankSector Rank
ROA -93.02%
ROE -105.12%
ROIC N/A
ROA(3y)-36.82%
ROA(5y)-82.65%
ROE(3y)-41%
ROE(5y)-258.41%
ROIC(3y)N/A
ROIC(5y)N/A
AVTE Yearly ROA, ROE, ROICAVTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

AVTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVTE Yearly Profit, Operating, Gross MarginsAVTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

AVTE has more shares outstanding than it did 1 year ago.
AVTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVTE Yearly Shares OutstandingAVTE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
AVTE Yearly Total Debt VS Total AssetsAVTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

AVTE has an Altman-Z score of -1.63. This is a bad value and indicates that AVTE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.63, AVTE perfoms like the industry average, outperforming 55.75% of the companies in the same industry.
There is no outstanding debt for AVTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.63
ROIC/WACCN/A
WACCN/A
AVTE Yearly LT Debt VS Equity VS FCFAVTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 8.78 indicates that AVTE has no problem at all paying its short term obligations.
The Current ratio of AVTE (8.78) is better than 75.40% of its industry peers.
A Quick Ratio of 8.78 indicates that AVTE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.78, AVTE is doing good in the industry, outperforming 75.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.78
Quick Ratio 8.78
AVTE Yearly Current Assets VS Current LiabilitesAVTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

AVTE shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.73%.
EPS 1Y (TTM)-8.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AVTE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.03% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.85%
EPS Next 2Y32.52%
EPS Next 3Y22.4%
EPS Next 5Y-4.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVTE Yearly Revenue VS EstimatesAVTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
AVTE Yearly EPS VS EstimatesAVTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVTE. In the last year negative earnings were reported.
Also next year AVTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTE Price Earnings VS Forward Price EarningsAVTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTE Per share dataAVTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as AVTE's earnings are expected to grow with 22.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.52%
EPS Next 3Y22.4%

More info and screens

0

5. Dividend

5.1 Amount

AVTE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEROVATE THERAPEUTICS INC

NASDAQ:AVTE (2/12/2025, 8:00:01 PM)

After market: 2.45 0 (0%)

2.45

-0.02 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners96.08%
Inst Owner Change-82.61%
Ins Owners0.08%
Ins Owner Change0%
Market Cap70.73M
Analysts48.89
Price Target2.38 (-2.86%)
Short Float %13.03%
Short Ratio16.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.59%
Min EPS beat(2)-2.57%
Max EPS beat(2)5.75%
EPS beat(4)1
Avg EPS beat(4)-1.43%
Min EPS beat(4)-6.37%
Max EPS beat(4)5.75%
EPS beat(8)2
Avg EPS beat(8)-2.46%
EPS beat(12)2
Avg EPS beat(12)-8.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)51.16%
EPS NY rev (1m)0%
EPS NY rev (3m)5.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS2.79
TBVpS2.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.02%
ROE -105.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.82%
ROA(5y)-82.65%
ROE(3y)-41%
ROE(5y)-258.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.78
Quick Ratio 8.78
Altman-Z -1.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)444.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.13%
EPS Next Y6.85%
EPS Next 2Y32.52%
EPS Next 3Y22.4%
EPS Next 5Y-4.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.66%
OCF growth 3YN/A
OCF growth 5YN/A